In a similar manner, induced expression or ectopic delivery of LTβR downstream mediators, CCL19 or CCL21, in the TME results in inhibition of tumor growth or complete rejection of established tumors associated with increased infiltration by CD3+CCR7+ T cells and/or DCs in a range of cancer models (32, 61–70). The gene discussed is CCL19; the disease is neoplasm.